Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in:

Open Access 01-12-2024 | Valproate | Research

Integrated proteomics and metabolomics analyses reveal new insights into the antitumor effects of valproic acid plus simvastatin combination in a prostate cancer xenograft model associated with downmodulation of YAP/TAZ signaling

Authors: Federica Iannelli, Rita Lombardi, Susan Costantini, Maria Serena Roca, Laura Addi, Francesca Bruzzese, Elena Di Gennaro, Alfredo Budillon, Biagio Pucci

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

Background

Despite advancements in therapeutic approaches, including taxane-based chemotherapy and androgen receptor-targeting agents, metastatic castration-resistant prostate cancer (mCRPC) remains an incurable tumor, highlighting the need for novel strategies that can target the complexities of this disease and bypass the development of drug resistance mechanisms. We previously demonstrated the synergistic antitumor interaction of valproic acid (VPA), an antiepileptic agent with histone deacetylase inhibitory activity, with the lipid-lowering drug simvastatin (SIM). This combination sensitizes mCRPC cells to docetaxel treatment both in vitro and in vivo by targeting the cancer stem cell compartment via mevalonate pathway/YAP axis modulation.

Methods

Here, using a combined proteomic and metabolomic/lipidomic approach, we characterized tumor samples derived from 22Rv1 mCRPC cell-xenografted mice treated with or without VPA/SIM and performed an in-depth bioinformatics analysis.

Results

We confirmed the specific impact of VPA/SIM on the Hippo–YAP signaling pathway, which is functionally related to the modulation of cancer-related extracellular matrix biology and metabolic reprogramming, providing further insights into the molecular mechanism of the antitumor effects of VPA/SIM.

Conclusions

In this study, we present an in-depth exploration of the potential to repurpose two generic, safe drugs for mCRPC treatment, valproic acid (VPA) and simvastatin (SIM), which already show antitumor efficacy in combination, primarily affecting the cancer stem cell compartment via MVP/YAP axis modulation. Bioinformatics analysis of the LC‒MS/MS and 1H‒NMR metabolomics/lipidomics results confirmed the specific impact of VPA/SIM on Hippo–YAP.
Appendix
Available only for authorised users
Literature
1.
2.
Jang A, Sartor O, Barata PC, Paller CJ. Therapeutic potential of PARP inhibitors in the treatment of metastatic castration-resistant prostate Cancer. Cancers (Basel). 2020;12(11).
3.
Mehtala J, Zong J, Vassilev Z, Brobert G, Gabarro MS, Stattin P, et al. Overall survival and second primary malignancies in men with metastatic prostate cancer. PLoS ONE. 2020;15(2):e0227552.PubMedPubMedCentralCrossRef
4.
Rizzo M. Mechanisms of docetaxel resistance in prostate cancer: the key role played by miRNAs. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188481.PubMedCrossRef
5.
Guerrero-Ochoa P, Rodriguez-Zapater S, Anel A, Esteban LM, Camon-Fernandez A, Espilez-Ortiz R et al. Prostate Cancer and the Mevalonate Pathway. Int J Mol Sci. 2024;25(4).
6.
Allott EH, Farnan L, Steck SE, Arab L, Su LJ, Mishel M, et al. Statin use and prostate Cancer aggressiveness: results from the Population-based North Carolina-Louisiana prostate Cancer Project. Cancer Epidemiol Biomarkers Prev. 2016;25(4):670–7.PubMedCrossRef
7.
Iannelli F, Roca MS, Lombardi R, Ciardiello C, Grumetti L, De Rienzo S, et al. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. J Exp Clin Cancer Res. 2020;39(1):213.PubMedPubMedCentralCrossRef
8.
Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98(3):604–10.PubMedPubMedCentralCrossRef
9.
Bruzzese F, Pucci B, Milone MR, Ciardiello C, Franco R, Chianese MI, et al. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death Dis. 2013;4(10):e878.PubMedPubMedCentralCrossRef
10.
Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–83.PubMedCrossRef
11.
Salem O, Hansen CG. The Hippo pathway in prostate Cancer. Cells. 2019;8(4).
12.
Liu X, Chinello C, Musante L, Cazzaniga M, Tataruch D, Calzaferri G, et al. Intraluminal proteome and peptidome of human urinary extracellular vesicles. Proteom Clin Appl. 2015;9(5–6):568–73.CrossRef
13.
Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteom. 2006;5(1):144–56.CrossRef
14.
Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13(9):731–40.PubMedCrossRef
15.
Lombardi R, Sonego M, Pucci B, Addi L, Iannelli F, Capone F, et al. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer. Mol Oncol. 2021;15(4):1005–23.PubMedPubMedCentralCrossRef
16.
Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.PubMedCrossRef
17.
Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. G:profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47(W1):W191–8.PubMedPubMedCentralCrossRef
18.
Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M, et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 2021;49(W1):W388–96.PubMedPubMedCentralCrossRef
19.
Liu T, Mendes DE, Berkman CE. Prolonged androgen deprivation leads to overexpression of calpain 2: implications for prostate cancer progression. Int J Oncol. 2014;44(2):467–72.PubMedCrossRef
20.
Li J, Xu X, Jiang Y, Hansbro NG, Hansbro PM, Xu J, et al. Elastin is a key factor of tumor development in colorectal cancer. BMC Cancer. 2020;20(1):217.PubMedPubMedCentralCrossRef
21.
Gong Y, Chippada-Venkata UD, Oh WK. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel). 2014;6(3):1298–327.PubMedCrossRef
22.
Zhang G, Miyake M, Lawton A, Goodison S, Rosser CJ. Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. BMC Cancer. 2014;14:310.PubMedPubMedCentralCrossRef
23.
Ozden F, Saygin C, Uzunaslan D, Onal B, Durak H, Aki H. Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival. J Cancer Res Clin Oncol. 2013;139(8):1373–82.PubMedCrossRef
24.
Zhang Y, Xi S, Chen J, Zhou D, Gao H, Zhou Z, et al. Overexpression of LAMC1 predicts poor prognosis and enhances tumor cell invasion and migration in hepatocellular carcinoma. J Cancer. 2017;8(15):2992–3000.PubMedPubMedCentralCrossRef
25.
Cattrini C, Barboro P, Rubagotti A, Zinoli L, Zanardi E, Capaia M, et al. Integrative Analysis of Periostin in primary and advanced prostate Cancer. Transl Oncol. 2020;13(7):100789.PubMedPubMedCentralCrossRef
26.
Hu Q, Tong S, Zhao X, Ding W, Gou Y, Xu K, et al. Periostin mediates TGF-beta-Induced epithelial mesenchymal transition in prostate Cancer cells. Cell Physiol Biochem. 2015;36(2):799–809.PubMedCrossRef
27.
Dong Q, Fu L, Zhao Y, Du Y, Li Q, Qiu X, et al. Rab11a promotes proliferation and invasion through regulation of YAP in non-small cell lung cancer. Oncotarget. 2017;8(17):27800–11.PubMedPubMedCentralCrossRef
28.
Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP/TAZ in mechanotransduction. Nature. 2011;474(7350):179–83.PubMedCrossRef
29.
Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer. 2006;5:17.PubMedPubMedCentralCrossRef
30.
Fabregat A, Sidiropoulos K, Viteri G, Forner O, Marin-Garcia P, Arnau V, et al. Reactome pathway analysis: a high-performance in-memory approach. BMC Bioinformatics. 2017;18(1):142.PubMedPubMedCentralCrossRef
31.
You X, Tian J, Zhang H, Guo Y, Yang J, Zhu C, et al. Loss of mitochondrial aconitase promotes colorectal cancer progression via SCD1-mediated lipid remodeling. Mol Metab. 2021;48:101203.PubMedPubMedCentralCrossRef
32.
Sajnani K, Islam F, Smith RA, Gopalan V, Lam AK. Genetic alterations in Krebs cycle and its impact on cancer pathogenesis. Biochimie. 2017;135:164–72.PubMedCrossRef
33.
Leandro JG, Espindola-Netto JM, Vianna MC, Gomez LS, DeMaria TM, Marinho-Carvalho MM, et al. Exogenous citrate impairs glucose tolerance and promotes visceral adipose tissue inflammation in mice. Br J Nutr. 2016;115(6):967–73.PubMedCrossRef
34.
Silva MF, Aires CC, Luis PB, Ruiter JP, L IJ, Duran M, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis. 2008;31(2):205–16.PubMedCrossRef
35.
36.
Moya IM, Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol. 2019;20(4):211–26.PubMedCrossRef
37.
Chen YA, Lu CY, Cheng TY, Pan SH, Chen HF, Chang NS. WW Domain-Containing proteins YAP and TAZ in the Hippo Pathway as key regulators in Stemness Maintenance, tissue homeostasis, and Tumorigenesis. Front Oncol. 2019;9:60.PubMedPubMedCentralCrossRef
38.
Santos DM, Pantano L, Pronzati G, Grasberger P, Probst CK, Black KE, et al. Screening for YAP inhibitors identifies statins as modulators of fibrosis. Am J Respir Cell Mol Biol. 2020;62(4):479–92.PubMedPubMedCentralCrossRef
39.
Hao F, Xu Q, Wang J, Yu S, Chang HH, Sinnett-Smith J, et al. Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice. PLoS ONE. 2019;14(5):e0216603.PubMedPubMedCentralCrossRef
40.
Koohestanimobarhan S, Salami S, Imeni V, Mohammadi Z, Bayat O. Lipophilic statins antagonistically alter the major epithelial-to-mesenchymal transition signaling pathways in breast cancer stem-like cells via inhibition of the mevalonate pathway. J Cell Biochem. 2019;120(2):2515–31.PubMedCrossRef
41.
Mi W, Lin Q, Childress C, Sudol M, Robishaw J, Berlot CH, et al. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration. Oncogene. 2015;34(24):3095–106.PubMedCrossRef
42.
Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021;6(1):153.PubMedPubMedCentralCrossRef
43.
Jang HS, Lal S, Greenwood JA. Calpain 2 is required for glioblastoma cell invasion: regulation of matrix metalloproteinase 2. Neurochem Res. 2010;35(11):1796–804.PubMedPubMedCentralCrossRef
44.
Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res. 2007;13(10):2849–54.PubMedCrossRef
45.
Lin C, Blessing AM, Pulliam TL, Shi Y, Wilkenfeld SR, Han JJ, et al. Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling. Oncogene. 2021;40(9):1690–705.PubMedPubMedCentralCrossRef
46.
Sorrentino G, Ruggeri N, Zannini A, Ingallina E, Bertolio R, Marotta C, et al. Glucocorticoid receptor signalling activates YAP in breast cancer. Nat Commun. 2017;8:14073.PubMedPubMedCentralCrossRef
47.
Li Y, Wang J, Zhong W. Regulation and mechanism of YAP/TAZ in the mechanical microenvironment of stem cells (review). Mol Med Rep. 2021;24(1).
48.
Zanconato F, Cordenonsi M, Piccolo S. YAP and TAZ: a signalling hub of the tumour microenvironment. Nat Rev Cancer. 2019;19(8):454–64.PubMedCrossRef
49.
Shi X, Young CD, Zhou H, Wang X. Transforming growth factor-beta signaling in Fibrotic diseases and Cancer-Associated fibroblasts. Biomolecules. 2020;10(12).
50.
Noguchi S, Saito A, Nagase T. YAP/TAZ signaling as a Molecular Link between Fibrosis and Cancer. Int J Mol Sci. 2018;19(11).
51.
Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218.PubMedPubMedCentralCrossRef
52.
Liu P, Zhang C, Liao Y, Liu J, Huang J, Xia M, et al. High expression of PTPRM predicts poor prognosis and promotes tumor growth and lymph node metastasis in cervical cancer. Cell Death Dis. 2020;11(8):687.PubMedPubMedCentralCrossRef
53.
Vallianou NG, Kostantinou A, Kougias M, Kazazis C. Statins and cancer. Anticancer Agents Med Chem. 2014;14(5):706–12.PubMedCrossRef
54.
Frick M, Dulak J, Cisowski J, Jozkowicz A, Zwick R, Alber H, et al. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis. 2003;170(2):229–36.PubMedCrossRef
55.
Tate R, Zona E, De Cicco R, Trotta V, Urciuoli M, Morelli A, et al. Simvastatin inhibits the expression of stemness–related genes and the metastatic invasion of human cancer cells via destruction of the cytoskeleton. Int J Oncol. 2017;51(6):1851–9.PubMedCrossRef
56.
Cai Z, Deng Y, Ye J, Zhuo Y, Liu Z, Liang Y, et al. Aberrant expression of citrate synthase is linked to Disease Progression and clinical outcome in prostate Cancer. Cancer Manag Res. 2020;12:6149–63.PubMedPubMedCentralCrossRef
57.
Abdel-Mawgoud AM, Lepine F, Deziel E. A chiral high-performance liquid chromatography-tandem mass spectrometry method for the stereospecific analysis of enoyl-coenzyme A hydratases/isomerases. J Chromatogr A. 2013;1306:37–43.PubMedCrossRef
58.
Zhang J, Ibrahim MM, Sun M, Tang J. Enoyl-coenzyme A hydratase in cancer. Clin Chim Acta. 2015;448:13–7.PubMedCrossRef
59.
Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005;78(1):60–8.PubMedCrossRef
60.
Salimi A, Gholamifar E, Naserzadeh P, Hosseini MJ, Pourahmad J. Toxicity of lithium on isolated heart mitochondria and cardiomyocyte: a justification for its cardiotoxic adverse effect. J Biochem Mol Toxicol. 2017;31(2).
61.
62.
Dalla Pozza E, Dando I, Pacchiana R, Liboi E, Scupoli MT, Donadelli M, et al. Regulation of succinate dehydrogenase and role of succinate in cancer. Semin Cell Dev Biol. 2020;98:4–14.PubMedCrossRef
63.
Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, et al. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol. 2012;180(3):895–903.PubMedPubMedCentralCrossRef
64.
Zhang LF, Liu LS, Chu XM, Xie H, Cao LJ, Guo C, et al. Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats. Acta Pharmacol Sin. 2014;35(3):363–72.PubMedPubMedCentralCrossRef
65.
Malenda A, Skrobanska A, Issat T, Winiarska M, Bil J, Oleszczak B, et al. Statins impair glucose uptake in tumor cells. Neoplasia. 2012;14(4):311–23.PubMedPubMedCentralCrossRef
66.
Khan S, Jena G. Valproic acid improves glucose homeostasis by increasing Beta-cell proliferation, function, and reducing its apoptosis through HDAC inhibition in Juvenile Diabetic Rat. J Biochem Mol Toxicol. 2016;30(9):438–46.PubMedCrossRef
67.
Rakitin A. Does Valproic Acid have potential in the treatment of diabetes Mellitus? Front Endocrinol (Lausanne). 2017;8:147.PubMedCrossRef
68.
Kumar D, Gupta A, Mandhani A, Sankhwar SN. Metabolomics-derived prostate cancer biomarkers: fact or fiction? J Proteome Res. 2015;14(3):1455–64.PubMedCrossRef
69.
Jiang Y, Cheng X, Wang C, Ma Y. Quantitative determination of sarcosine and related compounds in urinary samples by liquid chromatography with tandem mass spectrometry. Anal Chem. 2010;82(21):9022–7.PubMedCrossRef
70.
Koutros S, Meyer TE, Fox SD, Issaq HJ, Veenstra TD, Huang WY, et al. Prospective evaluation of serum sarcosine and risk of prostate cancer in the prostate, lung, colorectal and ovarian Cancer Screening Trial. Carcinogenesis. 2013;34(10):2281–5.PubMedPubMedCentralCrossRef
71.
72.
Elisi GM, Santucci M, D’Arca D, Lauriola A, Marverti G, Losi L et al. Repurposing of drugs targeting YAP-TEAD functions. Cancers (Basel). 2018;10(9).
Metadata
Title
Integrated proteomics and metabolomics analyses reveal new insights into the antitumor effects of valproic acid plus simvastatin combination in a prostate cancer xenograft model associated with downmodulation of YAP/TAZ signaling
Authors
Federica Iannelli
Rita Lombardi
Susan Costantini
Maria Serena Roca
Laura Addi
Francesca Bruzzese
Elena Di Gennaro
Alfredo Budillon
Biagio Pucci
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-024-03573-1

Other articles of this Issue 1/2024

Correction: MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome

Spatial and single-cell explorations uncover prognostic significance and immunological functions of mitochondrial calcium uniporter in breast cancer

Circular RNA circ_ARHGEF28 inhibits MST1/2 dimerization to suppress Hippo pathway to induce cisplatin resistance in ovarian cancer

CRHBP, a novel multiple cancer biomarker connected with better prognosis and anti-tumorigenicity

  • Open Access
  • Research

Syntaxin6 contributes to hepatocellular carcinoma tumorigenesis via enhancing STAT3 phosphorylation

Retraction Note: MCM3AP-AS1/miR-876-5p/WNT5A axis regulates the proliferation of prostate cancer cells

  • Open Access
  • Retraction Note

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits